The huge exopeptidase, tripeptidyl-peptidase II (TPP II), appears to be involved in a large number of important biological processes. It is present in the cytosol of most eukaryotic cells, where it removes tripeptides from free amino termini of longer peptides through a 'molecular ruler mechanism'. Its main role appears to be general protein degradation, together with the proteasome. The activity is increased by stress, such as during starvation and muscle wasting, and in tumour cells. Overexpression of TPP II leads to accelerated cell growth, genetic instability and resistance to apoptosis, whereas inhibition or downregulation of TPP II renders cells sensitive to apoptosis. Although it seems that humans can survive without TPP II, it is not without consequences. Recently, patients with loss-of-function mutations in the TPP2 gene have been identified. They suffer from autoimmunity leading to leukopenia and other consequences. Furthermore, a missense mutation in the TPP2 gene is associated with a sterile brain inflammation condition mimicking multiple sclerosis. This review will summarise what is known today regarding the activity and structure of this very large enzyme complex, and its potential function in various cellular processes. It is clear that more research is needed to identify natural substrates and/or interaction partners of TPP II, which can explain the observed effects in different cellular contexts.
enzyme has been ongoing since then. Previous review articles have summarised the information obtained during the first three decades [2e6] . This review will therefore mainly focus on developments achieved during the last decade and will only provide a brief summary of previous research.
TPP II is a self-compartmentalised peptidase, forming a large homooligomeric complex with limited access to the active site [7] . As the name implies, TPP II removes tripeptides sequentially from free N-termini of longer peptides, with a broad specificity [1, 8] . In addition, it also displays endopeptidase activity [9, 10] , albeit working at a considerably lower rate. TPP II is present in almost all eukaryotes, from fission yeast to plants and animals [11] . The broad substrate specificity and widespread distribution within organs and species suggest that TPP II is involved in general cytosolic protein turnover, presumably together with the proteasome. The fact that these two enzyme complexes have recently been shown to colocalise in the cytosol supports this notion [12] . Interestingly, some recent results demonstrate that patients with mutations in the gene encoding TPP II (TPP2) tend to suffer from autoimmune diseases, leading to leukopenia [13, 14] . The underlying features of TPP II, which may be involved, will be developed in this review.
Activity
Through its exopeptidase activity, which has a slight preference for cleavage after hydrophobic amino acids, TPP II removes N-terminal tripeptides. A free amino terminus in the substrate is essential for this activity [1, 8] . It has been demonstrated that the exopeptidase activity is dependent on two glutamic acids, Glu-305 and Glu-331 (using the numbering for the human and murine enzymes), which interact with the free N-terminus of the substrate [15] , thus forming a 'molecular ruler'. The corresponding amino acid residues in TPP II from Drosophila melanogaster (Glu-312 and Glu-343) were shown to be essential for binding the charged amino terminus of the substrate [16] . The authors concluded that Glu-312 was particularly important for blocking the S4 site in the substratebinding pocket (Fig. 1) .
TPP II seems to be essential for the degradation of peptides >15 amino acids [18] , but smaller substrates are also degraded with high efficiency [1, 8] . Early investigations using enkephalins demonstrated that cleavage of the first bond is faster if the substrate had a C-terminal extension [19] . The substrate binding site in TPP II therefore appears to be extended on the S 0 -side, i.e. the part of the enzyme that binds amino acids on the C-terminal side of the scissile peptide bond (Fig. 1 ). An extended substrate-binding site could explain the endopeptidase activity of TPP II, facilitating the binding of peptides, despite blockage of the S4-site. The endopeptidase activity of TPP II was first reported as being trypsin-like [9] , but has later been shown to be more promiscuous. Mass spectrometric analysis of the products when using the HIV peptide Nef [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] and a 37-mer (LL37) as substrates established that TPP II can cleave its substrate after hydrophobic, polar, positively and negatively charged amino acids [10] . Mutation of Glu-331 to Gln did not affect the endopeptidase activity. A FRET-substrate based on the Nefpeptide demonstrated that the K M for this substrate was of the same order as that for the chromogenic substrate AAF-pNA (12 mM), but that the catalytic efficiency was five orders of magnitude lower. Two intrinsically disordered protein domains, ACTR (75 amino acids) and pKID (35 residues) , could be degraded by TPP II through both exo-and endopeptidase activities, thus demonstrating that even large substrates can access the catalytic site of the complex. However, given the extremely low catalytic efficiency of the endopeptidase activity, its physiological relevance may be questionable [10] .
Inhibition
No natural inhibitors of TPP II have been reported to date. However, a number of synthetic inhibitors have been identified and used to investigate the functional importance of the enzyme in vitro and in vivo. As TPP II is a serine peptidase, it is sensitive to general irreversible protease inhibitors directed towards catalytic serine residues, such as diisopropyl fluorophosphate (DFP) and phenyl methyl sulphonyl fluoride (PMSF). It is also inhibited by some thiolreactive compounds such as N-ethylmaleimide [8] . Furthermore, specific inhibitors of TPP II are also known, with the most common being butabindide [20] . It is a reversible inhibitor with a K i in the nM range. However, butabindide is not stable in serum, which makes it less suitable for cell culture studies [18] . Recently, a specific irreversible inhibitor of TPP II, with a diphenylphosphonate targeting the catalytic serine residue, has been developed [21] . The inhibitor, named B6, is more useful than butabindide since it is more potent (>60 efold) and considerably more stable. However, B6 is not commercially available currently. Z-Gly-Leu-Ala was used as a TPP II-specific inhibitor [22] , but Tsurumi et al. reported that it was not active towards TPP II [23] and it did not inhibit purified human TPP II in vitro in our hands (B. Tomkinson and S. Eklund, unpublished observation).
Ala-Ala-Phe-chloromethyl ketone (AAF-CMK) has also been used as an inhibitor of TPP II [24e26]. This inhibitor is commercially available, readily inhibits TPP II, and is both stable and membrane permeable. However, it must be stressed that it is by no means a specific TPP II inhibitor, since it also inhibits the chymotrypsin-like activity of the proteasome [27] , as well as puromycin-sensitive aminopeptidase, bleomycin [28] and potentially also other intracellular peptidases. Villasevil et al. [29] demonstrated that the treatment of cells with AAF-CMK induced the formation of aggregates in the cytosol (aggresomes), similar to what can be seen with proteasome inhibitors, although effects varied among cell types. The aggresomes formed were dependent on microtubules and were located around the centrosomes. It was demonstrated that the formation of aggregates was not due to inhibition of TPP II, since neither butabindide nor TPP II gene silencing using siRNA had this effect [29] . The authors therefore suggested that the true target of AAF-CMK is an enzyme working upstream of the proteasome. Interestingly, they noted that the inhibitory effect towards TPP II was decreased in cell lysates, and they suggested that aminopeptidases attack AAF-CMK in cells in vivo [29] . It will therefore be important to investigate what the targets of the potential degradation products AF-CMK or F-CMK will be. Such results may shed some light on the conflicting results from experiments using this inhibitor. For example, the related inhibitor, N(alpha)-tosyl-Lphenylalanine chloromethyl ketone (TPCK), induces caspasedependent apoptosis in human B-cell lines [30] . Apparently, it is important not to draw extensive conclusions from studies based on AAF-CMK, which is both unspecific and whose fate has not been thoroughly investigated in live cells. 
Structure
TPP II is the largest peptidase complex described so far. The Drosophila enzyme is about 6 MDa, while the human enzyme is somewhat smaller, 4.5e5 MDa [12, 31] . Each subunit of the human enzyme consists of 1249 amino acids, corresponding to 138 kDa. Monomers spontaneously form ring-shaped dimers in a head-to head orientation. These can, in turn, oligomerize into multimeric complexes in a concentration dependent process [31, 32] ( Fig. 2A) . Thus, the protein forms hollow, twisted, strands, which ultimately form spindle-like structures with lengths of about 55 nm and widths of about 28 nm. The complexes of mammalian enzymes appear to be heterogeneous and consist of 8e9 dimers per strand, i.e. 32e36 monomers per spindle structure [12, 33] . In contrast, TPP II from Drosophila melanogaster is more homogenous, with spindles containing 40 monomers apparently dominating the complexes, hence, the larger size for the Drosophila enzyme [31] . Mammalian TPP II has been reported to also occasionally appear as longer strands in vivo [12] . The tendency for the purified human enzyme to form longer strands in vitro was also noted some 30 years ago, but its potential relevance was not understood at the time [34] . It is therefore interesting that large (>10 MDa) complexes/aggregates of TPP II have been detected in HEK293 cell extracts from cells overexpressing different variants of murine TPP II. The experiments show that both active site mutants [35] and a splice variant of TPP II, with 13 additional amino acids in the C-terminal part, can form the larger complexes [36] . How different changes in the structure affect the size of the complexes and whether they are of functional importance remain to be investigated.
The structure of TPP II from Drosophila was determined through a hybrid approach (Fig. 2 ). The structure of dimeric TPP II was first determined using X-ray crystallography, and subsequently docked into high-resolution structures of the oligomeric complex, obtained by single particle cryo-electron microscopy [7] . The structure of the human enzyme was later obtained by a combination of cryoelectron microscopy and molecular dynamics. Thus, a comparative model of the human dimer structure was fitted into the complex [33] . Both structures reveal that TPP II is a self- compartmentalising enzyme, as previously suggested [3] . The active site is buried inside the hollow strand, and is only accessible via narrow openings (27 Â 27 Å or 27 Â 23 Å, respectively) in the structure. There appears to be a continuous open chamber inside each strand of the complex, which may facilitate diffusion of substrates from one active site to another [33] . Since access to the active site is restricted, it is logical that TPP II is unable to cleave intact proteins and instead only acts on smaller or unfolded peptides (up to 75 amino acids) [10] .
The enzyme is activated upon oligomerisation [31, 37] and is almost 10-fold more active in the spindle-form than in the dimer form. The determination of its structure made it possible to the propose a mechanism for the activation of TPP II upon oligomerisation. In the X-ray structure of TPP II from Drosophila melanogaster, the so-called L2-loop is displaced and the alpha-helix containing the Ser of the catalytic triad is partially unfolded (cf. Fig. 2C ). In the hybrid structure of the human oligomeric complex, the catalytic Ser is in its proper place for catalysis, possibly due to refolding as a result of oligomerisation [33] . However, it should be pointed out that the dimers used for crystallisation were inactive, and it cannot be excluded that the position of the L2 loop is an artefact that does not reflect the true structure of the partially active dimers [7] . More in depth information regarding the activation mechanism will have to await more detailed structural information using active enzyme.
Evolution
TPP II is a serine peptidase of the subtilisin type (clan SB) and belongs to the subfamily S8A [38] . However, it is distinct from other subtilases, with respect to both activity and structure. Most subtilases are monomeric, extracellular, endopeptidases. In contrast, TPP II is an oligomeric, cytosolic, exopeptidase. According to Eriksson et al. an enzyme that has the same enzymatic activity and the characteristic structural features of TPP II can be regarded as a true homologue [11] . The tripeptidyl-peptidase activity of TPP II depends on two conserved glutamate residues [15] , while the structural features include a subtilisin-like catalytic domain, with a 200 amino acid insert between the catalytic Asp and His residues ("DH-insert") and a long C-terminal extension (>500 amino acids) ( Fig. 2E) . A homologue should also form an oligomeric complex [11] . Based on these criteria, sequence signatures were developed that could be used to identify true TPP II homologues [11] . These are widespread in eukaryotes, but only a few prokaryotic homologues have been identified to date, which are considered to be the result of a horizontal gene transfer [6, 11] .
It is interesting to consider the driving forces for the evolution of this complex enzyme [4, 6] . Full-length TPP II appears to have emerged in a primitive eukaryote. The broad range of organisms containing TPP II-like proteins suggests that a primitive form of TPP II was present already in the last universal common ancestor. The earliest form of a TPP II-like protease appears to be an extracellular protease, containing a smaller part of the beta-sheet rich C-terminal extension ("domain D", Fig. 2E ) [6] . The DH-insert was also a fairly early addition during evolution. The C-terminal helix domain (blue in Fig. 2E ), which is essential for complex formation, is present only in true homologues; moreover, these homologues have also lost their signal sequence, thus suggesting that when TPP II became cytosolic, the ability to form the oligomeric complex was gained. In order to protect the cell from unwanted proteolysis, it is possible that loss of the signal sequence provided the evolutionary pressure for developing a self-compartmentalising enzyme [6] .
It can also be noted that only the full-length homologues contain the glutamate residues that are essential for the characteristic tripeptidyl-peptidase activity [4] . This suggests that oligomerisation might also be linked to the tripeptidyl-peptidase activity. It can be speculated that oligomerisation is connected to the evolution of the exopeptidase activity. It is noteworthy that many other exopeptidases are also self-compartmentalising, e.g. leucine aminopeptidase [39] , bleomycin hydrolase [40] and Daminopeptidase DppA [41] .
Subtilases are activated upon binding of calcium. It is interesting to note that the part of TPP II that is homologous to the calciumbinding pocket in subtilisin is in close vicinity to the L2 loop, which is unstructured in the crystal structure of dTPP II (Fig. 2D ). It is suggested as changing the conformation upon oligomerisation [7, 33] . Therefore, the change in calcium concentration when TPP II became intracellular may also be a driving force for evolution of the oligomeric complex [4] .
Physiological function
Alternative functions of proteases range from unspecific proteolysis, indiscriminative to protein sequence or structure, to very specific cleavage at sites defined both by sequence and structure. Exact physiological function(s) for TPP II have not yet been established, i.e. very few natural substrates for TPP II have so far been identified. The picture that has emerged is that TPP II is a multipurpose peptidase, involved in a number of different processes [3] . Considering that evolution is tinkering, not engineering [42] , it is not surprising that the same peptidase is involved in different physiological contexts.
General intracellular protein-turnover
A role for TPP II as a house-keeping enzyme, providing amino acids for new protein synthesis, has been suggested [2e6]. Since tripeptides are good substrates for many exopeptidases, the production of tripeptides can speed up the release of free amino acids ( Fig. 3 ). There are situations where a pool of free amino acids is critical. For example, in order to maintain protein synthesis during starvation, it is necessary to obtain essential amino acids through protein degradation. The increased TPP II activity observed in situations of enhanced general proteolysis, such as muscle wasting [43] , cancer cachexia [44] and amino acid starvation [45] is therefore logical.
Knockout experiments show that TPP II can be deleted without any obvious phenotypical changes from the plant Arabidopsis thaliana [46] and the fission yeast Schizosaccharomyces pombe [11] . However, experiments with mice give somewhat conflicting results. According to McKay et al., deletion of the gene encoding TPP II (i.e. Tpp2) is embryonically lethal [47] , while gene-trapped mice with less than 10% residual TPP II activity showed no obvious phenotype [48] . Also, Huai et al. reported an immunosenescencelike phenotype for their knockout mice [49] . The observation that TPP II can be deleted without deleterious effects for an organism does not mean that TPP II is without a physiological role. On the contrary, it confirms that the process of producing free amino acids is so important that there appears to be a redundancy in the number of cytosolic proteases with overlapping specificities, such as thimet oligopeptidase, puromycin-sensitive aminopeptidase etc.
[50e52]. In fact, loss of TPP II leads to an increased lysosomal degradation in order to maintain the pool of free amino acids [13] , as discussed in section 7.
TPP II has been suggested to fulfil a role downstream of the proteasome in cytosolic protein turnover [2e6], since the proteasome does not produce free amino acids but peptides ranging from 3 to 22 amino acids [53] (Fig. 3) . A physical interaction between the two proteolytic complexes was recently demonstrated [12] , thus, supporting this notion. The authors showed that the two complexes are spatially associated in rat primary cultured neuronal cells by cryo-electron microscopy. TPP II was located mainly in the cytosol, often near microtubules or SER, but not in direct contact with membranes. About 50% of the detected TPP II particles were associated with proteasome particles, i.e. within 110 nm. However, since there are about 20 times as many proteasomes as TPP II particles in neurons, only 7% of the proteasome particles would have TPP II particles in their vicinity. No direct physical contact or preferred orientation between the two complexes was noted [12] . An important question is if the two enzymes are located in "degradation hot spots".
The perinuclear ER-rich region of cells is considered to be such a "degradation hot spot", since this is the primary proteolytic centre for degradation of defective ribosomal products (DRiPs) by the proteasome. However, recent data demonstrated that TPP II was diffusely dispersed within the cytoplasm of colon adenocarcinoma cells [54] . A novel fluorescence-tagged proteasomal inhibitor was used to induce formation of aggresomes in the cells. Upon inhibition of the proteasome, TPP II co-localised with the aggresomes. In the early stages, it was dispersed within the central part of the structure; however, in the mature aggresome, TPP II formed a spherical mantle surrounding the core of proteasome and polyubiquinated proteins [54] . The authors propose that the small amount of TPP II in the perinuclear region is sufficient for normal protein breakdown, but when the proteasome is impaired, TPP II is recruited in order to support some proteasomal function [54] . An alternative interpretation is that TPP II itself is a substrate for proteasomal degradation, explaining why it is aggregated in this position (cf. section 6.2).
Function in cancer, cell proliferation, apoptosis and stress
In addition to its beneficial role in general protein turnover, TPP II has also been shown to be involved in other processes, which appear not to be directly connected to this role. Thus, TPP II is important for malignancy, cell proliferation, apoptosis and stress response ( Fig. 4) . Consequently, it has been suggested to be a potential drug target [55e57]. This has been supported by the observation that the expression of TPP II is increased in a number of tumour cells, e.g. in Burkitt's lymphoma and EL-4 cells, where inhibition of TPP II renders the cells sensitive to apoptosis [26, 45] . More recently, it was shown that TPP II was significantly upregulated, both at mRNA and protein level, in seven oral squamous cell carcinoma (OSCC) derived cells as compared to its expression in normal human keratinocytes. Moreover, the expression was correlated with tumour size in primary OSCCs and suppression of the expression of TPP II inhibited cell proliferation [58] . It has also been shown that overexpression of TPP II leads to accelerated cell growth, resistance to apoptosis and increased genetic instability due to errors in centrosome duplication [59, 60] . Thus, TPP II appears to be involved in critical events that control cell division and apoptosis, but its exact role in these important processes remains to be elucidated. It has still not been established if the peptidase activity of the enzyme is involved or if the multimeric protein complex acts as a scaffold for interacting proteins involved in signalling pathways. Some attempts to determine its mechanism of action are summarised below.
It was shown that the increased expression of TPP II in Burkitt's lymphoma is coupled to the oncogene c-MYC [26] , but the corresponding protein c-myc does not directly lead to an increased expression of TPP II [56] . Nevertheless, TPP II is necessary for c-myc mediated centriole overduplication, since down-regulation of TPP II by siRNA or treatment with butabindide efficiently stops this process [56] . Overexpression of TPP II alone caused centriole multiplication, thus, corroborating earlier observations [59] . A fraction of Fig. 3 . The role of TPP II in intracellular protein degradation downstream of the proteasome. Its main function is to degrade peptides into tripeptides, thus, facilitating the formation of free amino acids (cf. Section 6.1). It also appears to be involved in creating or trimming some peptides for antigen presentation (cf. Section 6.4). The Pac-man-like symbols illustrate other cytosolic peptidases involved in the formation of free amino acids.
TPP II was localised to the centrosome, but the authors concluded that the precise role of TPP II in centriole biogenesis remains to be determined [56] . It has also been suggested that overexpression of TPP II leads to mislocalisation of MAD2, which physically interacts with the spindle assembly checkpoint to inhibit the activity of the anaphase promoting complex [58] . Knockdown of TPP II expression in OSCC cells by shRNA leads to the proper localisation of MAD2 to kinetochores and also up-regulation of CCNB1. The authors suggest that down-regulation of TPP II could mimic the effect of treatment with microtubule inhibitors [58] .
The effect of inhibition of TPP II in tumour cells has also been investigated using a proteomics approach. In these experiments, neuroblastoma cells (SH-SY5Y) were treated with butabindide or an irreversible variant of the inhibitor (B6) as well as shRNAknockdown (65% silencing) [21] . The proteomics data revealed that ERK2, which is also known as MAPK1, is connected to most of the proteins that have a changed expression after TPP II inhibition. It was shown that inhibition of TPP II leads to a marked decrease in phosphorylated, active pERK1/2 in the nucleus, but not in the cytosol. However, the mechanism for the effect of TPP II inhibition is still not known, since no protein kinase activity of TPP II has been reported [21] . Even though the mechanism has not been elucidated, it is clear that down-regulation of signal transduction downstream of growth factors and mitogenic stimuli would control transcription of genes involved in cell cycle, cell proliferation and cell growth. Therefore, this could explain why inhibition of TPP II renders cells sensitive to apoptosis. MAPK has previously been implicated in TPP II signalling [22, 61] .
Even though TPP II is a cytosolic enzyme, it was reported that it is translocated to the nucleus, in response to g-irradiation of transformed cell lines [55] , where it promoted p53 expression [22] . This was not confirmed in other investigations [23, 62] , even though a role for TPP II in DNA damage response was observed. Nevertheless, in this context, it is interesting to note that TPP II has been shown to interact with p53 [63] . Through in situ proximity ligation assay (PLA), it was demonstrated that TPP II physically interacts with the tumour suppressor MYBBP1A and the cell cycle regulator protein CDK2 [64] as well as with p53 and SIRT7, a deacetylase important in tumorigenesis and neurodegeneration [63] . It was suggested that TPP II is involved in a protein-interaction network [57] , but the exact function of this network has yet to be established. It has previously been suggested that TPP II could compensate for loss of the proteasome in cells with compromised proteasome activity [9, 65] , but this was later disputed, when it was demonstrated that the cells still had proteasomal activity and that the inhibitor AAF-CMK was not specific for TPP II [29, 66] . Evidently, TPP II cannot replace the proteasome, even though it seems to be upregulated in cells with reduced proteasome activity. An important question is if this is a compensatory effect, to ensure the supply of free amino acids for continued protein synthesis, or if it is a secondary effect. TPP II has a long half-life (49 ± 5 h) [21] , but it has been shown to be ubiquinated [67] and could therefore be a potential substrate for proteasomal degradation. It is possible that the interplay between TPP II and the proteasome is the key to explaining the role of TPP II in these important processes. If a feedback inhibition mechanism exists, it is possible that inhibition of TPP II could lead to dysfunction of the proteasome due to accumulation of peptides. If TPP II can compensate for loss of the proteasome in some aspects [5] , but not all, overexpression of TPP II could promote survival in situations that normally would lead to apoptosis. It has been reported that inhibitors of apoptosis (IAPs), substrates for proteasomal degradation, are stabilised in cells with high expression of TPP II and low expression of the proteasome [45] .
It is noteworthy that the ubiquitin-proteasome system is involved in the degradation of a large number of proteins involved in cell cycle progression and apoptosis, including the proteins involved in the TPP II protein-interaction network [57] . For example, MYBBP1A [68] , p53 [69] and CDK2 [70] are all degraded by the proteasome, and SIRT7 controls hepatic lipid metabolism by regulating the ubiqutin-proteasome pathway [71] . c-Myc is a target for proteasomal degradation, at least under some circumstances [72, 73] , and the centrosome has been suggested to act as a scaffold for ubiquitin-mediated proteasomal degradation. Centrosomal proteasomes appear to be involved in a large number of processes such as centrosome function, cell cycle progression, neuronal morphology and antigen presentation (reviewed in Ref. [74] ). It can therefore be speculated that the elusive role of TPP II in the important functions discussed above is connected to its interaction with the proteasome. An important focus for future studies should be to investigate the interaction between these two proteolytic systems in more detail regarding degradation of specific substrates involved in cell cycle regulation, centrosome duplication and apoptosis.
Degradation of CCK
More than 20 years ago, it was demonstrated that the neuropeptide cholecystokinin (CCK) was degraded and inactivated by a membrane-bound form of TPP II [20] . The enzyme was supposed to be bound through a GPI-anchor [20] , but subsequent reports showed it to be located on the cytosolic side of the plasma membrane [75] . To date, no other publications have investigated the membrane bound form of TPP II. The investigation of neuronal cells by cryo-electron microscopy [12] did not reveal any association with membranes; however, in that study, only TPP II complexes were identified. It cannot be ruled out that the membraneassociated forms are dimers or other oligomers, not identifiable through cryo-electron microscopy.
The specific TPP II-inhibitor butabindide could reduce foodintake in rats, and the effect was mediated by CCK A -receptors [20] . In one investigation, inhibition of TPP II by RNAi blocked adipogenesis and heterozygous Tpp2 mutant mice was lean although food intake was normal [47] . This pro-adipogenic effect of TPP II was shown to be independent of the peptidase activity [47] . However, it was not confirmed in other studies of knockout mice [48, 49] . Despite the potential interest in developing TPP IIinhibitors as potential drugs for treating overeating syndromes, no further developments in this area has, to my knowledge, been reported.
Antigen processing
Antigen presentation through MHC Class I is an intricate process that involves generation of peptides, transport of peptides into ER and loading of the peptides on MHC-class I antigens (see Refs.
[76e79] for recent reviews). MHC Class I molecules are expressed more or less ubiquitously. The antigens presented can be detected by CD8 þ T cells, and this process is essential for detection and destruction of cancer cells or cells infected by viruses; it is thus an essential part of cell-mediated immunity. In contrast to the MHC Class I-associated peptides, the MHC Class II-associated peptides represent extracellular proteins and self-proteins degraded in the endosomal pathway. Antigens from the MHC Class II repertoire are also presented by the MHC Class I system through crosspresentation [78] . However, the system is also involved in autoimmune reactions [78] , if an immune response towards normal proteins is elicited. The ubiquitin-proteasomal system has long been recognised as essential for generation of the antigenic epitopes, but a large number of other cytosolic peptidases are also involved in the process [77e79].
The involvement of TPP II in antigen processing could be the most studied aspect of the potential physiological role of the enzyme (Fig. 2) . The results have been partly conflicting. It has been demonstrated that TPP II is essential for the formation of some epitopes independently of the proteasome, e.g. the Nef epeptide from HIV [80] , latent membrane protein 1 epitopes [81] and influenza nucleoprotein [82] and that it is important in crosspresentation of an epitope of the melanoma antigen NY-ESO [83] . However, the importance of TPP II in generation of ligands for MHC Class I presentation has also been questioned [84, 85] . In particular, the formation of the influenza epitope is controversial, and could in part be dependent on a defective proteasome [86] . TPP II has also been shown to have a function in N-terminal trimming, i.e. removing tripeptides from longer peptides to form ligands [18, 87, 88 ]. It appears that TPP II is essential for trimming precursors of >15 amino acids [18, 87] but is dispensable for production of the majority of MHC Class I antigens [87] . For trimming of shorter precursors, a number of other cytosolic peptidases can also be involved in the process, e.g. bleomycin hydrolase, puromycin-sensitive aminopeptidase, leucine aminopeptidase, thimet oligopeptidase, aminopeptidase B, dipeptidyl peptidase 9 and prolyl oligopeptidase [79] . Generation of the epitope pp65 495-503 from human CMV is determined by the balanced activities of cytosolic and ER peptidases [89] . The cytosolic peptidases, in particular, TPP II and leucine aminopeptidase, destroy the epitope, whereas the ER peptidases ERAP1 and ERAP2 increase the formation thereof. Aminopeptidase B and prolyl oligopeptidase were identified as new players in the antigen processing machinery. Prolyl oligopeptidase could have a positive effect on antigen presentation as it removes Pro residues that are a hindrance for the TAP transporters [89] . The general conclusion appears to be that the main function of TPP II is in the destruction of epitopes [48, 90] . Thus, it was shown that the overall antigen presentation increased 1.4-fold in mice, where TPP II was knocked out [90] . Furthermore, an increased MHC Class I expression was noted in gene-trapped mice, and it was concluded that the main role was in destruction of epitopes [48] .
Even if TPP II is of limited importance in the bulk production of epitopes for antigen presentation [77] , it is still essential for the production of some epitopes [80] and destruction of others [91] . It is important to remember that only about 0.02% of the peptides generated by the proteasome is estimated to survive for presentation [92] . The destruction of epitopes could also be important in some specific situations, for example, for Pigmentation-associated melanocyte differentiation factor (PMEL, also gp100 or Pmel17). This protein is expressed in >90% of metastatic melanomas. Proteasomes generate a peptide for TAP-independent presentation, PMEL 209-217 , which is a promising phase 3 vaccine candidate for treating melanoma. Tumour-expressed epitopes presented by MHC class I are used as cancer vaccines since they can activate CD8 þ cytotoxic T cells. However, this epitope is degraded by TPP II, and inhibition of TPP II substantially increases PMEL 209-217 [93] . This was demonstrated using the inhibitors AAF-CMK and butabindide as well as TPP II knockdown through shRNAs, with similar effects. Thus, these results demonstrate that destruction of epitopes could sometimes be a detrimental function. It is also a challenging speculation that up-regulation of TPP II in tumour cells could be a way for cancer cells to evade detection by CD8 þ cytotoxic T lymphocytes. Destroying epitopes could also be an important function since presentation of certain epitopes could lead to autoimmunity. In this context, it is interesting that some allele variants of the ERassociated proteases ERAP1 and ERAP2 are associated with susceptibility to several autoimmune diseases [94, 95] .
Involvement in diseases
Mutations in the TPP2 gene have been identified as the causing agent in three different diseases with autoimmunity as a common theme. This highlights the importance of TPP II in the immune system.
An autosomal recessive loss of function mutation in the TPP2 gene causes recurrent infections, autoimmunity and neurodevelopment delay [13] . In one family with two affected children, a nonsense mutation (c2343 g) introduces a stop codon, and the protein is truncated after amino acid 781. The other family had two affected children who were homozygous for a missense mutation. The mutation gives rise to the variant G500D, with TPP II in low amounts (60e80% less than normal in peripheral blood monocytes). It is speculated that the mutation could interfere with complex formation, as amino acid no. 500 would be in the interface between the two strands [13] . In order to explain how the loss of functional TPP II could lead to the observed phenotype, a large number of experiments have been performed, both on cells derived from TPP II deficient gene-trapped mice [48] and on normal mouse fibroblasts treated with butabindide. It was demonstrated that the amount of intracellular free amino acids was markedly decreased after inhibition of TPP II with butabindide. This was a transient effect since the amount of free amino acids had returned to normal after 6e12 h. It is shown that inhibition of TPP II and the decrease in the total amount of free amino acids leads to mTOR activation, TFEB translocation into nucleus and an increase in lysosomal biogenesis [13] . The increased lysosomal degradation appears to compensate for the loss of active TPP II, both in cells from patients, in butabindide treated cells and in cells from TPP II deficient mice. There is decreased glycolysis in TPP II inhibited or gene-trapped cells, and the authors show that this is due to an increased lysosomal degradation of hexokinase 2 (HK2) by chaperon-mediated uptake into the lysosomes [13] . The hexokinase variant HK2 is important for aerobic glycolysis (i.e. lactate production in the presence of oxygen). Activated T-cells are dependent on aerobic glycolysis to meet their increased biosynthetic needs e.g. for production of IL-2 and INF-g. Overexpression of HK2 restored both glycolysis and INFg production. The effect on aerobic glycolysis would affect both adaptive and innate immunity. Therefore, macrophages from one of the patients were studied and shown to produce less IL-1b but normal amounts of TNF-a [13] . The authors conclude that the metabolic effect is the main cause of the primary immune deficiency, and propose the name Triangle disease: TPP II related immunodeficiency, autoimmunity, and neurodevelopmental delay with impaired glycolysis and lysosomal expansion. The neurodevelopmental delay observed in patients with loss-of-function mutation in the TPP2 gene is suggested to be the result of the metabolic effect [13] . In this context, it is interesting to note that it was shown that TPP II inhibition of neurons in the hippocampus leads to an excessive strengthening of synapses, indicating that TPP II activity is crucial for normal brain function [21] .
At about the same time, it was reported that a frameshift mutation in the TPP2 gene in a patient led to early-onset Evans syndrome, with primary immunodeficiency and progressive leukopenia [14] . An older sibling died from the disease, and the current patient has been treated with bone marrow transplantation. Cells from both knockout mice [49] and patients show increased MHC Class I expression, low proliferation and enhanced apoptosis in response to staurosporine. Pretreatment of control cells with butabindide also increased the sensitivity to staurosporine. Autoimmunity was seen in the patient, with antibodies against nuclear proteins. In addition, most of the investigated knockout mice expressed autoantibodies [14] . It is suggested that this is due to premature senescence also of B-cells, giving rise to a specific B-cell repertoire (ABCs), which are prone to giving rise to autoantibodies. Senescence appears to be stress-induced rather than replicative, since the length of the telomers are within the normal range. TPP II deficient mice have a normal polyclonal T-cell repertoire, but the repertoire is skewed in the patient, and is therefore not believed to be a direct consequence of the genetic defect [14] . In earlier investigations of knockout mice, it was demonstrated that fibroblasts showed premature senescence, leading to an aged appearance and premature death [49] . However, since the knockout mice could eliminate virus when challenged, it is clear that the phenotype is more severe in humans. Stepensky et al. report that cells from both patients and knockout mice show an enhanced IFN-g production, which is in contrast to the metabolic effect reported by Lu et al. [13, 14] . Apart from this, most of the observed differences between the two reports could be attributed to different approaches to elucidate the mechanism behind the phenotype. It is possible that the metabolic effect on glycolysis [13] also influence the immunosenescence observed in the patients [14] .
In contrast to the patients described above, other patients with a missense mutation in the TPP2 gene show a milder phenotype. In a search for the causing agent of a mild form of Multiple Sclerosis (MS) in a consanguineous family from Syria, a homozygous missense mutation in the TPP2 gene was detected [96] . The mutation changes Cys-28 to a Gly residue. Two affected siblings appear to have a decreased TPP II expression in blood cells, but the TPP II activity was not reduced in these cells. The patients have a mild form of MS, showed signs of respiratory tract infections during childhood and have a low lymphocytic count, which could reflect sub-threshold signs of Evans disease. This enzyme variant (C28G) is apparently active, and investigations of the corresponding murine variant in vitro shows that it has normal activity at least towards small chromogenic substrates (Tomkinson et al., unpublished data) . From the patient data, it is clear that the mutation is associated with a sterile brain inflammation mimicking MS. It was noted that TPP II was up-regulated at sites of active inflammatory demyelination in MS, and it is speculated that this could serve as a defence mechanism to ensure continued aerobic glycolysis, which is important for immune cell function [96] . It is possible that a decreased amount of TPP II in the blood cells, could reflect a reduced stability of the enzyme and therefore less protection towards sterile brain inflammation. An alternative explanation is that the mutation would change the substrate specificity of the enzyme. Even a marginal reduction of enzyme activity might not destroy an epitope that usually is destroyed. If this leads to the escape of selfpeptides, which may then be recognised by autoreactive T-cells, this could amplify the inflammatory process [96] .
The difference in phenotype between different patients with TPP II deficiencies demonstrates that not only the severity of the mutation but also the infectious challenges that the patients are subjected to most likely affect the phenotype. Since the C28G variant is still active, this mutation is not expected to result in such a severe phenotype as the nonsense mutations.
Conclusions
TPP II is an evolutionarily conserved enzyme that appears to be involved in a large number of important cellular functions. Beside peptide degradation, TPP II is also important for cell survival. It is involved in cancer and antigen processing for MHC Class I presentation. Since loss-of-function may result in human disease this demonstrates the physiological importance of TPP II. Despite many years of active characterisation of the enzyme, very few natural substrates have been identified. An important task for the future is to investigate the interplay between TPP II and the proteasome in more detail, which could explain the functional importance of TPP II on a molecular level. 
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